Komori
Other Disclosures197ATAUNS Laboratories,Inc.Pharmaceuticals

Notice of Participation in the ASAGI Labs Longevity Consortium

TAUNS Laboratories,Inc. has joined the ASAGI Labs Longevity Consortium, operated by the general incorporated foundation ASAGI Labs. Going forward, the Company will collaborate with participating academic institutions, companies, local governments and medical institutions on research and development related to longevity and the co-creation of new businesses.

Worth reading
54Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

ASAGI Labs Longevity Consortium
Applicable field (uses covered by this announcement)

Longevity, aging research, extending healthy life expectancy, life planning, social participation, diagnostic technology, data and AI, healthcare, research and development, and new business creation

Launch dateParticipation completed as of 6 August 2026
Relationship between the counterparty and the company
TAUNS Laboratories,Inc.197A
Relationship with the Company

The Company has joined the Consortium. No capital or personnel relationship is stated.

CounterpartyGeneral Incorporated Foundation ASAGI Labs

A general incorporated foundation. It serves as the Consortium's secretariat, and its representative director is Hayano Motoshi (早野元詞). It conducts research and development related to longevity, creates businesses, carries out joint research and social implementation through industry-government-academia collaboration, disseminates information, promotes public awareness, and makes policy recommendations. Date established: 1 June 2026. Website: https://www.asagiconsortium.com/

Impact on Business Performance

No impact on results is stated

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services CoveredASAGI Labs Longevity Consortium
CounterpartyGeneral Incorporated Foundation ASAGI Labs
Counterparty overviewA general incorporated foundation. It serves as the Consortium's secretariat, and its representative director is Hayano Motoshi (早野元詞). It conducts research and development related to longevity, creates businesses, carries out joint research and social implementation through industry-government-academia collaboration, disseminates information, promotes public awareness, and makes policy recommendations. Date established: 1 June 2026. Website: https://www.asagiconsortium.com/
Relationship with the CompanyThe Company has joined the Consortium. No capital or personnel relationship is stated.
Launch dateParticipation completed as of 6 August 2026
Applicable areaLongevity, aging research, extending healthy life expectancy, life planning, social participation, diagnostic technology, data and AI, healthcare, research and development, and new business creation
Impact on Business PerformanceNo impact on results is stated
Items this document does not state (11)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Against a backdrop of social challenges including aging research, the integration of information using AI, and expanding healthcare demand associated with population aging, the Company's testing platform and data and AI infrastructure are highly compatible with the Consortium's activities, and opportunities for collaboration in research and development and new business creation are expected.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Participation in the ASAGI Labs Longevity Consortium | TAUNS Laboratories,Inc. (197A) timely disclosure | Komori